Genome-wide association studies have identified significant association between PLA2G1B gene polymorphisms and central adiposity in humans. This gene encodes the Group 1B phospholipase A2 protein (PLA2G1B) that hydrolyzes phospholipids to generate free fatty acids and lysophospholipids (lysoPL) in the digestive tract. Recent lipidomic analyses have also identified elevated lysoPL as a major obesity risk factor in humans, thus suggesting that PLA2G1B-mediated production of lysoPL may contribute to obesity and its related metabolic consequences. This project has documented previously that Pla2g1b inactivation in mice decreases intestinal lysoPL absorption, and as a consequence decreases hepatic fatty acid oxidation in protection against diet-induced obesity and glucose intolerance. This renewal application will delineate the mechanism by which intestinal lysoPL absorption suppresses hepatic fatty acid oxidation, and test the hypothesis that PLA2G1B-mediated lysoPL absorption and transport to the liver is a major contributing factor for diet-induced metabolic diseases including obesity, diabetes, and atherosclerosis. The second goal of this application is to delineate the molecular mechanism linking the common PLA2G1B polymorphism with decreased adiposity in humans.
Aim 1 will test the hypothesis that lysoPL suppresses hepatic fatty acid oxidation and promote diet-induced obesity and glucose intolerance by inducing transient opening of mitochondrial permeability transition pores and/or activating JNK stress signaling to suppress PPAR activity. The direct role of hepatic lysoPL toward these metabolic disorders will be assessed by determining if converting lysoPL to phospholipids by increasing lysoPC acyltransferase specifically in liver will improve fatty acid oxidation and ameliorate diet-induced metabolic disorders in Pla2g1b+/+ mice similar to that in Pla2g1b-/- mice.
Aim 2 is a proof of concept pre-clinical study to evaluate the efficacy of oral Pla2g1b inhibitor therapy in suppressing atherosclerosis in hypercholesterolemic Ldlr-null mice. The specific role of Pla2g1b will be ascertained in complementary studies comparing atherosclerosis development between Pla2g1b+/+Ldlr-/- and Pla2g1b-/- Ldlr-/- mice.
Aim 3 will identify the mechanism by which the common PLA2G1B polymorphism (rs5637;allelic frequency ~20%) is associated with reduced obesity in humans, testing the hypothesis that the synonymous G-to-A mutation alters an exon splicing enhancer sequence within exon 3 of the PLA2G1B gene, resulting in alternative splicing and deletion of the exon 3 domain to yield an inactive enzyme. Taken together, these studies will not only contribute valuable information toward understanding the mechanism by which PLA2G1B-induced lysoPL promotes metabolic disorders, thereby accelerating the development of PLA2G1B inhibitors for disease intervention, but will also help identify subjects that may benefit the most from this novel therapeutic strategy.

Public Health Relevance

Genome wide association studies and lipidomic analysis have identified PLA2G1B polymorphism and lysophospholipid levels as determinants of obesity/diabetes and related metabolic complications. This proposal addresses the cellular and molecular mechanisms by which lysophospholipids promote metabolic disorders and the relationship between PLA2G1B polymorphism with gene expression and enzyme activity. The clinical implication of this mechanism-based study is that results will contribute valuable information to improve and personalize treatment strategies to suppress diet-induced obesity and its related metabolic complications.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Pawlyk, Aaron
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Cincinnati
Schools of Medicine
United States
Zip Code
Hui, David Y (2016) Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease. Curr Opin Lipidol 27:507-12
Cash, J G; Hui, D Y (2016) Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice. Nutr Diabetes 6:e206
Hollie, Norris I; Konaniah, Eddy S; Goodin, Colleen et al. (2014) Group 1B phospholipase A? inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice. Atherosclerosis 234:377-80
Hollie, Norris I; Cash, James G; Matlib, M Abdul et al. (2014) Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function. Biochim Biophys Acta 1841:888-95
Hui, David Y (2012) Phospholipase A(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 23:235-40
Hollie, Norris I; Hui, David Y (2011) Group 1B phospholipase A? deficiency protects against diet-induced hyperlipidemia in mice. J Lipid Res 52:2005-11
Cash, J G; Kuhel, D G; Goodin, C et al. (2011) Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice. Int J Obes (Lond) 35:877-81
Labonte, Eric D; Pfluger, Paul T; Cash, James G et al. (2010) Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J 24:2516-24
Labonte, Eric D; Kirby, R Jason; Schildmeyer, Nicholas M et al. (2006) Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes 55:935-41